MK-677 Ibutamoren: The Complete Guide to Benefits, Dosage, and Research

Quick Facts

What MK-677 Ibutamoren Does & How It Works

What It Does - Functional Outcomes

• Raises growth hormone levels by stimulating the pituitary gland's own pulsatile GH release - not by delivering exogenous GH
• Increases IGF-1 (insulin-like growth factor-1) in a sustained, dose-dependent manner documented across multiple human trials
• Preserves and increases lean tissue mass during caloric restriction and in aging populations
• Accelerates bone remodeling by increasing both bone formation and bone resorption markers
• Increases energy expenditure in obese subjects
• Stimulates appetite through ghrelin receptor activation - a direct, predictable pharmacological effect
• Supports nitrogen retention during catabolic states such as dietary restriction

How It Works - Mechanism of Action

GHS-R1a Receptor Agonism and Pulsatile GH Release (Evidence: Human and Animal)

MK-677 binds to the growth hormone secretagogue receptor subtype GHS-R1a, which is located primarily in the hypothalamus and anterior pituitary gland. This binding mimics the action of ghrelin, the body's endogenous hunger hormone, and triggers the pituitary to release growth hormone in the pulsatile pattern the body naturally uses. Unlike continuous exogenous GH administration, this pulsatile release preserves the body's natural GH secretion rhythm. The result, documented across multiple human clinical trials, is a meaningful increase in 24-hour mean GH concentrations without suppressing the hypothalamic-pituitary-GH axis.

IGF-1 and IGFBP-3 Elevation (Evidence: Human - multiple trials)

The GH released in response to GHS-R1a activation travels to the liver, where it signals production of IGF-1 and its primary binding protein IGFBP-3. IGF-1 is the primary mediator of GH's anabolic effects on muscle, bone, and connective tissue. Across human trials at 25 mg daily, IGF-1 increases of 36-73% above baseline have been consistently documented and are sustained throughout the treatment period. IGFBP-3 rises in parallel, which moderates the fraction of free IGF-1 available to peripheral tissues.

Nitrogen Balance Reversal in Catabolism (Evidence: Human - Murphy et al., 1998, JCEM)

In a clinical study of healthy men under caloric restriction, MK-677 shifted nitrogen balance from negative to positive while placebo subjects remained in nitrogen deficit. Nitrogen balance is a direct measure of whether the body is in net protein breakdown or net protein building. A positive balance means the body is retaining more protein than it is losing - the biochemical prerequisite for lean tissue preservation during a caloric deficit.

Bone Remodeling Cycle Acceleration (Evidence: Human - Svensson et al., 1998, JCEM)

MK-677 at 25 mg daily increased both formation markers (carboxy-terminal propeptide of type I procollagen, osteocalcin) and resorption markers (NTX) in human subjects over eight weeks. This bidirectional acceleration of bone turnover means MK-677 speeds up the entire remodeling cycle - more building and more breakdown happening simultaneously - rather than specifically increasing net bone formation. The net long-term effect on bone mineral density has not been established in the published literature.

Adaptive Desensitization with Prolonged Use (Evidence: Animal - PMC6240568)

Rodent studies of prolonged MK-677 administration documented a compensatory response: the hypothalamus increased somatostatin (a GH inhibitor) production, while the pituitary downregulated somatostatin receptor-2 expression. No increase in pituitary GH mRNA was observed during extended dosing. This bidirectional adaptation is proposed as the mechanism behind tolerance or diminishing returns with long-term use, though direct confirmation in humans is not available.

MK-677 Ibutamoren Molecular Profile

Structure reference: View on PubChem - Ibutamoren (CID 178024) - Publishing team: retrieve 2D structure image from this link.

MK-677 Ibutamoren Uses & Benefits

Lean Mass Preservation and Body Composition

Users and researchers have studied MK-677 primarily for its ability to preserve and increase lean tissue, particularly during caloric restriction and in aging populations where lean mass naturally declines. The mechanism is direct: elevated GH and IGF-1 promote nitrogen retention and shift the body's protein balance toward net building rather than net breakdown. Human clinical trial data supports this outcome - a 12-month trial in elderly adults showed a 1.1 kg increase in fat-free mass in the MK-677 group versus a 0.5 kg decrease in the placebo group. The important caveat from the same trial: lean mass gains were not accompanied by measurable improvements in muscle strength or physical function on objective testing. (Evidence: Moderate - human trials - Nass et al., 2008)

Catabolism Reversal During Dietary Restriction

One of MK-677's clearest documented use cases is protecting lean tissue during periods of caloric deficit - a goal relevant to anyone cutting weight, recovering from illness, or managing age-related muscle wasting. The nitrogen balance study directly tested this: healthy men in a caloric restriction protocol who received 25 mg daily moved from negative to positive nitrogen balance, while placebo subjects remained in deficit. IGF-1 rose from 186 ng/mL to 264 ng/mL alongside the nitrogen change. This represents MK-677's most mechanistically direct human evidence. (Evidence: Moderate - human trial - Murphy et al., 1998, JCEM)

Bone Health and Remodeling

MK-677 is used by some practitioners and individuals interested in supporting bone density and bone health, based on its documented effects on bone turnover markers. Two separate human studies found meaningful increases in both formation and resorption markers within weeks of starting 25 mg daily dosing - confirming the compound activates the bone remodeling process. Whether accelerated remodeling translates to improved net bone density over years is not answered by the available evidence. (Evidence: Moderate - human trials - Svensson et al., 1998, JCEM)

Growth Hormone Deficiency Support

A dose-escalation study enrolled GH-deficient adults and found IGF-1 increases of 52-79% and 24-hour mean GH increases of 79-82% across doses of 10-50 mg daily. The response was greater in subjects with less severe deficiency. For this specific population, MK-677's oral bioavailability represents a meaningful practical advantage over injectable GH secretagogues. The same study found adverse clinical experiences in five of nine subjects even at the 10 mg starting dose - context that matters in a population already managing GH deficiency. This use case is investigational and not an approved indication. (Evidence: Moderate - human trial)

Aging and Longevity Applications

Declining GH and IGF-1 are well-documented features of normal aging, and MK-677's ability to elevate both through an oral route has made it appealing in longevity-focused protocols. The 12-month elderly trial directly tested a geriatric population, documenting sustained GH and IGF-1 elevation, lean mass preservation, and no serious drug-related adverse events in that cohort. The compound is also studied for its effects on sleep quality through GH's natural link to slow-wave sleep architecture. Users report improved sleep depth as one of the early subjective experiences. Long-term safety in healthy aging adults is not established. (Evidence: Moderate for body composition in elderly; Preliminary for sleep quality effects)

Where This Guide Comes From

MK-677 Ibutamoren Results & Timelines

Lean Mass and Body Composition

• Week 1-2: Appetite increase is typically the first and most reliably reported early effect - a direct consequence of ghrelin receptor activation. Sleep quality changes, particularly deeper or more vivid sleep, are commonly reported in the first one to two weeks.
• Week 2-4: Water retention and morning puffiness appear during this window for many users. Some report improved recovery from training - soreness resolving faster, joints feeling less stiff.
• Week 6-8: This is the range where meaningful body composition changes are most commonly first described in documented protocols. Lean mass gains become more apparent; some users note scale weight increases driven partly by retained water alongside genuine tissue changes.
• Week 12 and beyond: The 12-month elderly trial documented sustained fat-free mass differences at endpoint. Community protocols that run 12-16 weeks report this range as where compositional results are most visible, though gains come alongside the metabolic trade-offs described in the safety section.

Sleep Quality

• Week 1-2: Users most consistently report changes to sleep as among the earliest subjective experiences - improved depth of sleep and more vivid dreaming are the most frequently mentioned patterns in documented community protocols. These effects are pharmacologically consistent with GH's role in slow-wave sleep architecture.
• Week 3 and beyond: Sleep effects tend to remain consistent throughout a cycle for most users who report them, rather than habituating quickly.

Bone Turnover

• Week 2: Human research found bone formation markers elevated within two weeks of starting 25 mg daily.
• Week 8: Osteocalcin (a bone formation marker) was meaningfully elevated at the eight-week mark in the primary bone study.
• Beyond 8 weeks: Long-term bone density outcomes have not been measured in published research.

How to Administer MK-677 Ibutamoren

Oral

Oral administration is the only documented and studied route for MK-677, and it is the defining pharmacological characteristic that distinguishes this compound from every injectable growth hormone secretagogue. MK-677 is a stable synthetic small molecule that survives transit through the stomach and small intestine and reaches systemic circulation intact - unlike peptide-based GHRPs such as GHRP-2 and GHRP-6, which are cleaved by gastric acid and digestive enzymes before they can be absorbed. All human clinical trial data was generated with oral dosing. The compound is available as liquid solutions (most common), capsules, and research-grade powder - no injection equipment, no reconstitution, and no refrigeration required for most common consumer formats.

Bedtime dosing has been specifically studied and is pharmacologically rational: GH is predominantly released during slow-wave sleep, and aligning MK-677's peak receptor activation with the body's natural nocturnal GH release window is a logical approach. Community protocols most commonly use once-daily evening or bedtime dosing for this reason, and it also means the appetite stimulation - which can be significant - occurs while the user is asleep rather than throughout the waking day.

Subcutaneous Injection (SubQ)

SubQ injection is not an applicable administration route for MK-677. The compound's oral bioavailability makes injection unnecessary, and no injectable MK-677 formulation has been studied in clinical research.

Nasal / Intranasal

Intranasal administration has not been studied or validated for MK-677. Any nasal formulation would be a nonstandard custom preparation without a documented evidence base.

Topical

Topical administration has not been studied or validated for MK-677 and is not an applicable route for this compound.

MK-677 Ibutamoren Dosage & Cycle Length

MK-677's dosing is one of the more straightforward stories in the growth hormone secretagogue category - because actual human clinical trial data exists at specific doses. You do not have to rely entirely on extrapolation from animal models or community protocols. Here is what the published research used, and what real-world practice looks like on top of it.

Overall dosing range: 10-25 mg per day, taken orally - the range used across the majority of published human studies

How the goal shifts where you land:

• Low end of range (10-15 mg/day): Used in community protocols as a starting point to assess individual tolerance - particularly appetite effects, water retention, and sleep changes. The dose-escalation study in GH-deficient adults began at 10 mg, though adverse experiences were noted in the majority of that cohort even at this level, which is worth understanding before assuming a lower dose is automatically safer for everyone.
• Mid range (20-25 mg/day): The most widely studied dose in human trials and the most commonly cited full dose in documented protocols. The 12-month elderly trial, the nitrogen balance study, and the bone turnover studies all used 25 mg daily. This is the best-supported research dose.
• High end of range (30 mg and above): Used in some community protocols, particularly in bodybuilding contexts. Clinical research extended to 50 mg in the GH-deficient adult escalation study, which produced IGF-1 increases of 52-79%, though with increasing adverse experience rates. Community data suggests water retention, fatigue, and blood glucose effects become more prominent at higher doses.

Frequency: Once daily. The approximately 24-hour half-life of MK-677 supports a single daily dose rather than split dosing. Bedtime dosing has been specifically studied and is pharmacologically rational given the alignment with natural nocturnal GH release patterns.

Cycle length: Community protocols most commonly run 8-12 weeks followed by a break of 4-8 weeks. Extended protocols of 16-24 weeks are used by more experienced users in supervised or semi-supervised contexts. Clinical research has used continuous daily dosing for up to 12 months in monitored settings, with IGF-1 elevation sustained throughout. Whether continuous long-term use in healthy adults is appropriate is a separate safety question addressed in the side effects section.

Stepped entry protocol: A nine-week design appearing in clinical study data started participants at 5, 10, or 25 mg for the first two weeks to assess tolerance before moving to 25 mg daily for the remaining seven weeks. This graduated approach is reflected in many community protocols that start lower and titrate up.

Blood glucose monitoring: Given the documented insulin resistance effects across multiple studies, anyone running MK-677 should monitor fasting blood glucose periodically throughout a cycle. This is not optional context - it is the most practically important monitoring parameter for this compound.

MK-677 Ibutamoren Vial Sizes, Costs & Quality

MK-677 is not sold in vials - it does not require reconstitution. This is one of the practical advantages of an orally bioavailable compound. The market offers three primary formats: liquid solutions in dropper bottles, capsules, and research-grade powder.

Common product formats and sizes:

• Liquid solution: most commonly 30 mL or 60 mL bottles at 25 mg/mL concentration
• Capsules: typically 60-count bottles at 10 mg per capsule
• Research-grade powder: available in quantities from 5 mg to gram-scale for laboratory use

Typical cost range:

• Liquid solution (30 mL at 25 mg/mL): approximately $70-80 per bottle for U.S.-manufactured research-grade product at current market pricing, providing a 30-day supply at 25 mg/day
• Capsules (60 count at 10 mg each): approximately $70-90 per bottle; at 25 mg/day this requires multiple capsules per dose and becomes less economical per milligram
• Research-grade laboratory powder: significantly higher per-milligram cost than consumer formats; intended for scientific research rather than end-user preparation

Storage - liquid solution:

• Temperature: cool, dry place away from direct sunlight; minimize open-air exposure after opening
• Light sensitivity: keep away from direct light; amber or opaque bottles are standard for this reason

Storage - capsules:

• Temperature: cool, dry conditions; room temperature stable if kept away from heat and humidity

Storage - research-grade powder:

• Temperature: 2-8 degrees C per laboratory specifications
• This is a laboratory storage requirement, not typical for end-user liquid or capsule formats

Normal appearance: Liquid solutions are typically clear to slightly yellow in color. Capsules contain a powder fill that varies by manufacturer. Any liquid solution showing heavy cloudiness, visible particulates, or unusual discoloration should not be used.

Signs of degradation: Cloudiness in a previously clear liquid solution, change in color, unusual odor, or visible particulates are indicators that the product has degraded or was improperly manufactured.

Quality Considerations

The MK-677 market is saturated with products of varying quality, and the stakes are higher than with most compounds because it is taken daily at meaningful doses over extended cycles. The core problem is straightforward: without third-party testing, you have no way to verify that what is in the bottle matches what is on the label. Research-grade synthesis has real costs - when a product is priced significantly below market norms, something is being cut, whether that is synthesis purity, quality testing, or proper solvent ratios in liquid preparations. A meaningful portion of what is sold online originates from overseas facilities with no standardized oversight, no chain of custody documentation, and no independent purity verification - and contamination concerns, including heavy metal contamination, have been raised specifically within this category. U.S.-manufactured products with documented third-party certificates of analysis and traceable manufacturing processes represent a meaningful upgrade in confidence, even at higher per-bottle cost.

MK-677 Ibutamoren Side Effects & Safety

The safety picture for MK-677 is more complicated than most compounds in this category. Short-term tolerability in controlled studies is generally acceptable. The serious adverse event data - particularly the cardiovascular finding - requires honest and direct presentation.

Side Effect Spectrum

Contraindications

• Pre-existing heart failure or significant cardiovascular disease: This is the most critical contraindication. A clinical trial in GH-deficient adults was stopped early after 4 of 62 MK-677 subjects (6.5%) developed congestive heart failure compared to 1 of 60 placebo subjects (1.7%). The FDA has flagged this as a significant safety risk . Anyone with existing cardiac disease or heart failure history should not use this compound outside of direct medical supervision.
• Active or history of malignancy: Sustained IGF-1 elevation is a documented concern for tumor growth promotion. Individuals with a history of cancer or active malignancy should not use MK-677 without explicit guidance from an oncology-aware provider.
• Pre-existing diabetes or significant insulin resistance: MK-677 consistently worsens glucose control across multiple studies. Elevated fasting glucose and reduced insulin sensitivity are among the most reliably reproduced adverse effects, documented across clinical studies and safety reviews . In individuals with diabetes or pre-diabetes, this represents a compounding risk.
• Active liver disease or history of elevated liver enzymes: A case report of transaminitis following approximately two months of MK-677 use, resolving after discontinuation, establishes hepatotoxicity as a documented if uncommon risk .

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• End-stage renal disease: Studied in a registered trial (NCT00395291) but outcomes data not fully published - insufficient evidence to confirm safety in this population
• Individuals taking SARMs concurrently: Combined use has been associated with worsened lipid profiles and compounded liver enzyme elevations; use with caution and appropriate laboratory monitoring

Red Flags - Stop Use and Seek Medical Attention If:

• Significant shortness of breath, edema in the lower extremities, or rapid unexplained weight gain (potential signs of fluid overload or cardiac stress)
• Rapid or irregular heartbeat
• Marked fatigue out of proportion to activity level combined with swelling in the legs or ankles
• Significant right upper quadrant abdominal discomfort or yellowing of the skin or eyes (potential hepatic symptoms)
• Fasting blood glucose consistently above 126 mg/dL, or symptoms of high blood sugar including excessive thirst and frequent urination

Drug and Compound Interactions

MK-677 has not been studied extensively in combination with other compounds in controlled settings. The most important documented interaction concern is with selective androgen receptor modulators (SARMs): concurrent use has been associated with worsened serum lipid profiles and compounded liver enzyme elevations. Combining MK-677 with exogenous recombinant growth hormone is generally not recommended without medical supervision, as both compounds converge on the GH/IGF-1 axis and the risk of over-stimulation - including worsening insulin resistance and fluid retention - is meaningful. In individuals on medications affecting glucose metabolism such as metformin, insulin, or sulfonylureas, the additive insulin resistance effect of MK-677 is clinically relevant and requires monitoring.

MK-677 Ibutamoren Research & Studies

MK-677 has a more substantial human clinical trial record than the majority of compounds in the growth hormone secretagogue category. That is genuinely meaningful context. It also has the largest single trial in this space return a null result for its primary endpoint. Both facts belong in the same honest picture.

Pharmacokinetics & Metabolism

Absorption & Bioavailability {#absorption-bioavailability}

MK-677 is orally bioavailable - this is the central pharmacological fact that distinguishes it from peptide-based GHRPs. It is absorbed intact through the gastrointestinal tract and reaches systemic circulation in sufficient concentrations to produce documented GH and IGF-1 elevation across multiple clinical trials. The compound is stable in the GI environment, unlike peptide-based secretagogues that are degraded by gastric acid and proteolytic enzymes before reaching circulation.

Distribution {#distribution}

MK-677 exerts its primary effects at the GHS-R1a receptor in the hypothalamus and anterior pituitary. Detailed tissue distribution data in humans is not published in the accessible literature; most distribution understanding comes from receptor binding studies and the downstream hormonal effects documented across clinical trials.

Half-Life {#half-life}

Approximately 24 hours, based on the dosing schedules validated in clinical research. This supports once-daily dosing and is consistent with sustained IGF-1 elevation documented in daily-dosing trials. Precise pharmacokinetic curves have not been published in the accessible peer-reviewed literature reviewed for this article.

Metabolism & Elimination {#metabolism-elimination}

Detailed human metabolic and elimination pathway data for MK-677 is not available in the published literature reviewed. The compound is a synthetic small molecule; its hepatic metabolic fate is presumed but not fully characterized in published clinical pharmacology documentation.

Mechanistic Research

GHS-R1a Receptor Binding and GH Pulse Amplification (Evidence: Human and Animal - PMC6240568)

MK-677's mechanism begins at the GHS-R1a receptor, where it acts as a full agonist. Rat studies of prolonged MK-677 administration documented that the receptor response is not static - the hypothalamus upregulates somatostatin mRNA and protein during extended treatment, while the pituitary downregulates somatostatin receptor-2 expression. Somatostatin is the body's primary GH inhibitor. This bidirectional adaptation is proposed as the mechanism underlying the tolerance pattern observed with prolonged use, where GH pulses may remain elevated but downstream growth promotion decreases .

IGF-1 and IGFBP-3 Elevation (Evidence: Human - multiple trials)

Across multiple human clinical trials at 25 mg daily, IGF-1 increases of 36-73% above baseline have been consistently documented. These elevations are sustained over the full duration of studied treatment periods, including the 12-month elderly trial, which confirmed maintained IGF-1 elevation at both six and twelve months . IGFBP-3, the primary binding protein for IGF-1, rises in parallel, which moderates the bioavailability of free IGF-1 and may influence the net anabolic signal reaching peripheral tissues.

Bone Turnover Marker Stimulation (Evidence: Human - Svensson et al., 1998, JCEM)

MK-677 at 25 mg daily for eight weeks in obese males increased carboxy-terminal propeptide of type I procollagen by 23% at two weeks and osteocalcin by 15% at eight weeks - both markers of bone formation. Simultaneously, NTX, a resorption marker, increased 27-46%. This simultaneous bidirectional stimulation of bone remodeling is the key mechanistic finding: MK-677 accelerates the bone remodeling cycle rather than simply increasing net bone formation .

Nitrogen Balance Reversal in Catabolism (Evidence: Human - Murphy et al., 1998, JCEM)

In healthy men under caloric restriction, MK-677 at 25 mg daily moved nitrogen balance from -2.67 g/day to +0.31 g/day compared to -1.48 g/day in the placebo group (P less than 0.01). This nitrogen retention effect represents the most mechanistically direct evidence that MK-677 can shift the body from a catabolic to an anabolic state during dietary stress .

Condition-Focused Research

Lean Mass and Catabolism {#research-lean-mass}

The nitrogen balance study enrolled healthy men in dietary restriction and measured the effect of 25 mg oral MK-677 daily. Nitrogen balance shifted from negative to positive in the MK-677 group while remaining negative in placebo controls, and IGF-1 rose from 186 ng/mL to 264 ng/mL. The 12-month elderly trial followed with a longer-duration confirmation: fat-free mass increased 1.1 kg in the MK-677 group versus a 0.5 kg decrease in the placebo group, with sustained GH and IGF-1 elevation throughout. Notably, this fat-free mass increase was not accompanied by corresponding improvements in muscle strength or physical function on objective testing. (Evidence: Human - Nass et al., 2008, Annals of Internal Medicine)

Bone Health {#research-bone}

Two bone-focused human studies bracket the evidence here. The obese males study documented formation and resorption marker changes at 2 and 8 weeks at 25 mg daily . A separate elderly bone study found similar elevations in osteocalcin and bone-specific alkaline phosphatase at 10-25 mg doses over 2-4 weeks, coinciding with IGF-1 rises . Both confirm that MK-677 activates bone remodeling; neither provides long-term bone density outcome data. (Evidence: Human - Phung et al., 1999, JCEM)

Growth Hormone Deficiency {#research-ghd}

The dose-escalation study in GH-deficient adults tested 10, 25, and 50 mg daily in a sequential design, finding IGF-1 increases of 52-79% and 24-hour mean GH increases of 79-82%. The response was greater in subjects with less severe deficiency. Five of nine subjects at the 10 mg starting dose reported possibly drug-related adverse clinical experiences - a meaningful adverse event rate that the compound's community discussion rarely surfaces. (Evidence: Human - Chapman et al., 1997, JCEM)

Alzheimer's Disease - The Null Finding {#research-alzheimers}

The largest MK-677 trial ever conducted enrolled 563 Alzheimer's patients at 25 mg daily for 12 months (NCT00074529). IGF-1 rose 60-73% above baseline - the compound did exactly what it was expected to do hormonally. On every cognitive and functional outcome measure assessed (ADAS-Cog, ADCS-ADL, CDR-sob, CIBIC+), MK-677 showed no benefit over placebo. Alzheimer's disease progression was unaffected despite robust and sustained IGF-1 elevation throughout the trial . This null result is the most important piece of clinical evidence for understanding what MK-677 cannot do. (Evidence: Human - NCT00074529, ClinicalTrials.gov)

Cardiovascular Safety Signal {#research-cardiovascular}

A clinical trial in GH-deficient adults was stopped early following the emergence of congestive heart failure in 4 of 62 MK-677 subjects (6.5%) versus 1 of 60 placebo subjects (1.7%). The FDA has specifically cited this finding and flagged significant safety risks for patients with heart disease . Fluid retention - a consistent pharmacological effect of GH elevation - is the proposed mechanism. This finding is not theoretical; it is a primary reason the compound has not received regulatory approval.

Safety & Tolerability Research

Short-term tolerability data across 187 elderly adults in 2-9 week studies found no serious drug-related adverse events, with the compound generally well-tolerated at doses of 10-50 mg daily. The nitrogen balance study documented transient gastrointestinal symptoms and one case of fasting glucose elevation to 142 mg/dL . The 12-month elderly trial noted a cortisol increase of 47 nmol/L reaching statistical significance - the only study to report this finding . A published human case report (PMID 40675653) documented transaminitis resolving after MK-677 discontinuation, establishing hepatotoxicity as a documented if uncommon adverse event . The congestive heart failure signal in the GH-deficient adult trial remains the most clinically significant safety finding in the published record .

Research Limitations

The MK-677 research base has meaningful gaps specific to this compound. Most human trials are small - fewer than 100 participants - and study durations rarely exceed 12 months. No large-scale randomized controlled trial has demonstrated therapeutic efficacy in any approved indication. The FDA has noted small sample sizes, short durations, and inadequate follow-up as recurring limitations across the submitted evidence base . The largest completed trial returned a null result for its primary endpoint. Long-term safety data in healthy adults does not exist - all safety findings come from studies of specific patient populations. Mechanistic desensitization data comes entirely from rodent models, and translation to human physiology is not confirmed. Body composition improvements have not been accompanied by functional strength gains, limiting interpretability for performance-oriented users.

Is MK-677 Ibutamoren Legal? Regulatory & Sports Status

FDA status: MK-677 ibutamoren is not approved by the FDA for any human therapeutic indication. As of 2025, the FDA has explicitly concluded that ibutamoren is excluded from the definition of a dietary supplement, meaning it cannot legally be sold as a supplement in the United States. The FDA has issued warning letters related to products containing undisclosed ibutamoren and cited significant safety risks - including the cardiovascular finding - in its regulatory review of the compound [4, 9].

Research Use Only (RUO): MK-677 is classified as a research chemical and investigational compound in most jurisdictions. It is not approved for human therapeutic use in any major regulatory market. Its commercial availability as a research chemical exists in a regulatory gray zone that does not constitute medical authorization for human use.

WADA / USADA status: MK-677 is prohibited by the World Anti-Doping Agency (WADA) as a growth hormone secretagogue. It is prohibited both in- and out-of-competition, meaning athletes subject to WADA or USADA jurisdiction face sanctions if detected year-round, not only during competition windows .

Country-specific notes: Australia's sport integrity authorities have explicitly named ibutamoren as a prohibited substance with documented cardiovascular risks. In the United Kingdom, MK-677 is not a controlled drug but is not licensed for human use. Import and personal use laws differ significantly by jurisdiction - users outside the United States should verify local regulations independently .

Detection: A detection method for MK-677 has been developed and validated for anti-doping purposes. The compound's 24-hour half-life and known metabolite profile make it detectable within standard anti-doping screening panels. The specific detection window is not publicly specified in available anti-doping documentation .

MK-677 Ibutamoren vs. Alternatives

Commonly Paired With - Synergistic Stacks

• MK-677 + RAD-140 (Testolone): One of the most documented stacks in community protocols, combining MK-677's GH/IGF-1 elevation with RAD-140's selective androgen receptor activity for lean mass and recovery goals. The combination compounds both the anabolic signal and the adverse effect profile - lipid changes and liver enzyme elevations are more pronounced when these compounds are combined, and users running this stack should monitor laboratory values throughout.
• MK-677 + LGD-4033 (Ligandrol): Paired for mass-oriented goals in bodybuilding community protocols. LGD-4033 contributes directly to androgen receptor-mediated muscle protein synthesis while MK-677 elevates the GH/IGF-1 axis. Similar compounded risk considerations apply as with the RAD-140 combination.
• MK-677 + BPC-157: Used in recovery-focused protocols where users want GH/IGF-1 elevation from MK-677 combined with BPC-157's documented effects on connective tissue repair. BPC-157 is injectable (typically subcutaneous) while MK-677 is oral, so this combination does not eliminate the need for injections if BPC-157 is included. Stacking information is for educational context - individualized stack protocols live inside MPP.

Alternatives - When Another Compound May Be Considered

Sermorelin Sermorelin is a growth hormone releasing hormone analog that stimulates GH release through the GHRH receptor rather than the ghrelin receptor. It requires subcutaneous injection and has a much shorter half-life than MK-677, typically requiring twice-daily dosing or bedtime injection. For users with needle tolerance who want GH stimulation with a mechanism closer to endogenous GHRH signaling and a longer supervised clinical use record in certain contexts, sermorelin is the most frequently cited alternative.

GHRP-2 and GHRP-6 These peptide-based growth hormone releasing peptides share MK-677's receptor target (GHS-R1a) but require subcutaneous injection and have short half-lives requiring multiple daily injections. GHRP-6 produces stronger appetite stimulation than MK-677, while GHRP-2 is somewhat more GH-selective. For users who can tolerate injections and want shorter cycles or more control over GH pulse timing, these are the structural predecessors to MK-677 in the GHS category.

Tesamorelin Tesamorelin is an FDA-approved GHRH analog indicated for HIV-associated lipodystrophy. It requires injection and has a substantially higher-cost and more restricted access profile than MK-677 outside of its approved indication. For users in a supervised medical context specifically addressing metabolic or body composition changes associated with GH deficiency, tesamorelin represents the regulatory gold standard in this mechanistic space.

Comparison table:

Build Your MK-677 Protocol

FAQs

What is MK-677?

MK-677, also called ibutamoren, is a synthetic orally active small molecule that mimics the hunger hormone ghrelin to stimulate the body's own pulsatile release of growth hormone and downstream IGF-1. It is not a peptide - it has no amino acid sequence - despite frequently being grouped with peptide-based growth hormone secretagogues in community discussions. It was developed as an investigational drug candidate and has been studied in human clinical trials for applications including lean mass preservation, bone health, and growth hormone deficiency support, but has not received regulatory approval for any therapeutic indication.

What does MK-677 do?

MK-677 increases growth hormone and IGF-1 levels by binding to and activating the ghrelin receptor in the hypothalamus and pituitary gland. In human clinical research, this has translated to preservation of lean tissue during caloric restriction, increased fat-free mass in elderly adults over 12 months, acceleration of bone turnover markers, and increased energy expenditure in obese subjects. The most notable thing it did not do is slow Alzheimer's disease progression - the largest trial conducted returned a null result despite robust IGF-1 elevation throughout.

How long does MK-677 take to work?

Growth hormone and IGF-1 elevation begins within 24 hours of the first dose - peak GH of 55.9 mcg/L was measured after a single 25 mg dose in one clinical study. Subjectively, increased appetite and improved sleep quality are typically among the first reported experiences, often within the first week. Meaningful changes in body composition take longer - the 12-month elderly trial showed significant lean mass differences at its endpoint, and most community protocols describe compositional changes becoming noticeable around weeks 6-8 of consistent dosing.

What is the typical dose of MK-677?

The dose most consistently used across human clinical trials is 25 mg daily, taken orally once per day. Community protocols typically start at 10-15 mg to assess tolerance before moving to 25 mg. Doses of 10-50 mg have been studied in research settings, with 25 mg representing the best-supported research dose for most applications. Individual protocols vary based on goals, tolerance, and health status - MyPeptidePal builds personalized protocol ranges based on your specific situation.

Is MK-677 legal?

MK-677 is not FDA-approved for human use and has been explicitly excluded from the dietary supplement category by the FDA in the United States. It exists in most markets as a research chemical, which is a classification that does not authorize human therapeutic use. It is prohibited by WADA and USADA year-round, meaning athletes under anti-doping jurisdiction face sanctions if detected. Regulatory and legal status varies by country - users outside the United States should verify local laws and import regulations independently.

Can MK-677 be taken orally?

Yes - oral administration is the only documented and researched route for MK-677, and oral bioavailability is the compound's defining pharmacological characteristic. Unlike peptide-based GHRPs that are degraded by stomach acid and require injection, MK-677 is a stable synthetic small molecule that survives the gastrointestinal environment and reaches systemic circulation intact. All human clinical trial data was generated with oral dosing. It is available as liquid solutions, capsules, and powder - no injection or reconstitution required.

Does MK-677 suppress natural testosterone or require post-cycle therapy?

MK-677 does not work through androgen receptors and does not suppress testosterone production. It is not a SARM, not a prohormone, and not a testosterone analog - it works exclusively through the GH/IGF-1 axis via ghrelin receptor activation, leaving the hypothalamic-pituitary-gonadal axis intact. Post-cycle therapy as used after androgenic compounds or SARMs is not relevant to MK-677 use on its own. This is a meaningful distinction from many of the compounds it is commonly stacked with.

Does MK-677 cause insulin resistance, and should I be concerned about blood sugar?

Reduced insulin sensitivity and elevated fasting blood glucose are among the most consistently reproduced adverse effects across MK-677 studies, documented across clinical studies and FDA safety reviews . One study documented fasting glucose reaching 142 mg/dL in a participant . For users with normal glucose metabolism and no metabolic risk factors, this effect is worth monitoring but may be manageable. For anyone with pre-existing insulin resistance, pre-diabetes, or type 2 diabetes, this represents a meaningful compounding risk that warrants serious caution and medical discussion before any MK-677 use.

Is MK-677 safe for long-term use?

Long-term safety in healthy adults has not been established - no large-scale study has specifically characterized the safety profile of extended MK-677 use in this population. The available long-term data comes from a 12-month trial in elderly adults, which showed the compound was generally tolerated but noted cardiovascular concerns significant enough to stop a separate trial early. The FDA has noted that the research base features small sample sizes, short durations, and inadequate follow-up . The honest answer is that we do not have the data to call long-term MK-677 use safe.

What is the difference between MK-677 and actual growth hormone?

Exogenous recombinant human growth hormone delivers GH directly into the bloodstream via injection, creating continuously elevated levels that bypass the body's pulsatile release system and suppress natural GH production over time. MK-677 does not deliver GH - it stimulates the pituitary to produce and release more of its own GH in the pulsatile pattern the body naturally uses, without suppressing endogenous production. The practical advantages are oral dosing and preserved axis function; the trade-off is a ceiling on how much GH elevation is achievable compared to direct exogenous GH administration.

Final Thoughts on MK-677 Ibutamoren

MK-677 ibutamoren occupies a genuinely unusual position in the growth hormone secretagogue space. It has more human clinical trial data than almost any non-approved compound in this category. It is orally bioavailable in a field where almost everything else requires a needle. And it works - growth hormone goes up, IGF-1 goes up, lean mass is preserved and increased in human studies, bone turnover accelerates, and nitrogen balance shifts in the right direction during caloric restriction. That is a more substantial human evidence base than most comparable compounds can claim.

The part that gets less airtime deserves equal weight. A clinical trial was stopped early because heart failure developed at a higher rate in the MK-677 group than in the placebo group. The largest single trial ever conducted on this compound found no therapeutic effect in its primary disease indication despite robust IGF-1 elevation throughout. Insulin resistance is not a theoretical concern - it is a documented, reproducible finding across multiple studies, and it compounds over time in ways that matter for metabolic health. Long-term safety data in healthy adults simply does not exist. These are not small print items to scroll past. They are the context within which any honest evaluation of MK-677 has to sit.

The right framework for approaching MK-677 is neither the biohacking community's enthusiasm nor reflexive dismissal. It is the same framework that applies to any compound with real human data and real unanswered questions: understand what the evidence actually shows, understand what it does not show, know which risks apply to your specific situation, and build a protocol around your specific parameters rather than a one-size-fits-all template from an internet forum. That is exactly where MyPeptidePal is built to help - taking the broad evidence picture from this guide and translating it into a protocol that accounts for your health history, your goals, and what you are actually trying to accomplish.

References

1. Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601-611.

2. Mozid, A. M., Tauber, M., Sherlock, M., & others. (2018). Effects of prolonged MK-677 administration on GH axis regulation in rat models. PubMed Central.

3. Murphy, M. G., Bach, M. A., Plotkin, D., Bhara, J., Storey, L., & others. (1998). Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover and fat-free mass in obese males. Journal of Clinical Endocrinology & Metabolism, 83(7).

4. U.S. Food and Drug Administration. (2025). FDA briefing document on ibutamoren (MK-677): safety review and regulatory status.

5. Svensson, J., Lonn, L., Jansson, J. O., Murphy, G., Wyss, D., Krupa, D., Cerchio, K., Polvino, W., Gertz, B., Boseaus, I., Sjostrom, L., & Bengtsson, B. A. (1998). Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677 increases fat-free mass and bone markers. Journal of Clinical Endocrinology & Metabolism, 83(2), 257-261.

6. Chapman, I. M., Bach, M. A., Van Cauter, E., Farmer, M., Krupa, D., Taylor, A. M., Schilling, L. M., Cole, K. Y., Skiles, E. H., Pezzoli, S. S., Hartman, M. L., Veldhuis, J. D., Fristrom, W. K., & Thorner, M. O. (1997). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism, 82(10), 3455-3463.

7. Case report: Transaminitis following MK-677 ibutamoren use. (2025). PubMed.

8. Phung, L. A., & others. (1999). MK-677 effects on bone markers in elderly subjects. Journal of Clinical Endocrinology & Metabolism.

9. U.S. Food and Drug Administration. (2025). Warning letter: AgeBox Inc. regarding ibutamoren-containing products marketed for human use.

10. Sport Integrity Australia. (2024). Ibutamoren (MK-677) information: anti-doping classification and detection.

11. National Institutes of Health, ClinicalTrials.gov. (2004). Study of MK-677 in Alzheimer's disease (NCT00074529).

12. National Library of Medicine, PubChem. Ibutamoren compound summary (CID 178024).